ArticleDermatology and therapy2018
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.
Sebastian Spindeldreher et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
24 papers cite it
this paperpooled ittrialcites it